Icahn drops Genzyme stock
Carl Icahn has divested the 1.5 million shares of Genzyme he acquired in the third quarter of 2007. The Genzyme investment was no longer listed as part of Icahn Capital Management's portfolio by the end of 2007, according to SEC filings. The stock's value took a healthy bump when the management firm's third-quarter filing became public. Icahn's attention is focused on Genzyme's Cambridge, Mass., neighbor Biogen Idec, where he holds 8.3 million shares and is making a play to control the board at the annual meeting in May...
You may also be interested in...
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.
When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.